Receptor Interaction For TCDD And Its Structural Analogs

TCDD 及其结构类似物的受体相互作用

基本信息

项目摘要

The primary goals of this project are the use to determine fundamental molecular mechanisms of action and toxicity of ligands of the aromatic hydrocarbon receptor (AHR) and the application of this mechanistic information to address specific needs in the assessment of human health risk posed by exposure to these compounds. There are a wide variety of AHR ligands including persistent lipophilic polyhalogenated aromatic hydrocarbons (e.g. 2,3,7 8-tetrachlorodibenzo-p-dioxin (TCDD), polychlorinated-dibenzodioxins, -dibenzofurans and -biphenyls), non-persistent polycyclic aromatic hydrocarbons (e.g. 3-methylcholanthrene) and endogenous/dietary ligands (e.g. indole and tryptophan metabolites). The polyhalogenated aromatic hydrocarbons are persistent environmental pollutants, and their lipophilicity and subsequent bioaccumulation through the food chain results in chronic lifetime low-level human exposure. In rodent studies, these persistent AHR ligands have been shown to induce a wide variety of biological and pathological effects including alteration in expression of specific AHR-regulated gene subsets, altered cell growth, endocrine disruption and cancer. Alterations in expression of these specific regulated genes occur via a mechanism that involves a high affinity interaction of dioxins and related ligands with the AHR, a basic helix-loop-helix protein that functions as a ligand-activated transcription factor. While the relationship between exposure and observed health effects has been well established in rodent models, considerable scientific controversy exists in the assessment of human health risk posed by the persistent daily low-level exposure to these potent environmental contaminants. This is due to the fact that the mechanisms relating activation of the AHR by either persistent or non-persistent ligands to the subsequent development of adverse health effects have not been established. Specifically our research is focussed in three areas (1) Determination of the mechanism of carcinogenicity of TCDD in rodents (2) Identification of cell specific and species differences in the AHR-dependent transcriptional response network between humans and rodents (3) Assessment of the suitability of relative potency factors for the prediction of cancer risk posed by TCDD and structurally related persistent polyhalogenated aromatic hydrocarbons. Specific Aim 1. Mechanism of hepatocarcinogenicity of TCDD : The induction of liver tumors by TCDD in the female rat has consistently been used by regulatory agencies in the establishment of appropriate guidelines for human exposure to dioxin. One of the most well characterized responses to TCDD is the induction of cytochromes P450 such as CYP1B1, CYP1A1 and CYP1A2. While TCDD has been shown to be a potent tumor promoter in the rat liver, the mechanism of tumor induction by TCDD and relationship to induce gene expression in these rodent models is not known. It is hypothesized that the persistent TCDD mediated activation of the AHR and induction of the cytochromes P450 CYP1 and associated estradiol hydroxylase activities results in an estrogen-dependent induction of oxidative stress that leads to indirect genotoxicity and altered hepatocyte growth response. Specific Aim 2. Cell specific and species differences in AHR-dependent transcriptional response: Human exposure to dioxins has been associated with increased risk of human lung disease and cancer. In rodents, TCDD exposure induces lung tumors in rats and mice and recent studies have shown that in rats, TCDD induces metaplasia and hyperplasia in the alveolar/bronchiolar epithelium. The specific aim of this project is to determine the species concordance of transcriptional response to AHR ligands in lung epithelia. Specific Aim 3 . Relative potency of toxicity of TCDD and structurally related persistent polyhalogenated aromatic hydrocarbons; When considering the risk of human exposure to dioxins, it is well established that exposure is as complex mixtures of polyhalogenated aromatic hydrocarbons rather than to a single specific congener. To assess the risk of these mixtures the Toxic Equivalency Factor (TEF) approach has been developed to characterize the toxicity of mixtures of those persistent compounds that bind to the AHR and possess "dioxin-like" activity. The specific aims are two-fold; initially we shall determine individual relative potencies for dioxin-like compounds and mixtures of these compounds, and the impact of co-exposure of non-dioxin-like PCBs on the potency for dioxin-like PCBs. Secondly, we shall determine the additivity of relative potencies for dioxins and their ability to predict the potency of mixtures of dioxins to induce gene expression, hormonal dysregulation, toxicity, and cancer. Research accomplishments. Demonstrated that the induction of 8-oxo-deoxyguanosine adducts by TCDD as a marker of TCDD induced indirect oxidative DNA damage is female-specific, estrogen dependent, and requires persistent chronic exposure. These data support the hypothesis that TCDD may be indirectly genotoxic via a chronic induction of oxidative stress as a result of AHR receptor-mediated induction of cytochrome P450 isozymes and subsequent production of redox active estrogen metabolites. Defined the TCDD-responsiveness of a recently established in vitro cell model of normal human lung Clara cells, the target for TCDD action in both human and rodent lung in vivo. Used toxicogenomic and quantitative expression analyses to investigate the comparative dose-dependent transcriptional network of TCDD action in "normal" vs malignant human peripheral lung epithelial cell lines. Identified pathways involved in cytokine and growth factor-signalling and cell adhesion as specific targets altered by TCDD that may be involved in TCDD induced neoplasia in the human lung. Integrated quantitative gene expression data into a current state-of-the-art physiologically based pharmacokinetic and mechanistic model for TCDD action. Used this refined model as a replacement for the use of simple default pharmacokinetic methods for the benchmark-dose estimation of body burdens of TCDD associated with a 1% excess risk for non-cancer endpoints. These analyses indicated that the use of default methods may lead to underestimation of the non-cancer risk posed by exposure to TCDD. Dose response modeling of CYP1 enzyme activity from interim necropsies was conducted. Analysis of independent model fits indicated that relative potency factors based on independent ED50 determinations were inclusive of the current TEF values for the respective chemicals tested and that the relative potency of the TEF mixture, designed using the current TEFs was inclusive of the expected value of 1.0. A rigorous statistical analysis of simultaneous model fits of the induced enzyme activity data indicated the relative potencies for the three congeners for CYP1A2 differed significantly from published TEF values. However, the relative potency of the mixtures of these congeners was not significantly different from additivity, when the new estimated potencies were applied.
该项目的主要目标是确定芳香烃受体(AHR)配体的基本分子作用机制和毒性,并应用这种机制信息,以满足评估接触这些化合物所造成的人类健康风险的具体需要。AHR配体种类繁多,包括持久性亲脂性多卤芳烃(如2,3,7 -四氯二苯并-对二恶英(TCDD)、多氯二苯并二恶英、-二苯并呋喃和-联苯)、非持久性多环芳烃(如3-甲基胆蒽)和内源性/膳食配体(如吲哚和色氨酸代谢物)。多卤芳烃是持久性环境污染物,其亲脂性和随后通过食物链的生物积累导致人类长期低水平暴露。在啮齿动物研究中,这些持续的AHR配体已被证明可诱导多种生物和病理效应,包括改变特定AHR调节基因亚群的表达、改变细胞生长、内分泌紊乱和癌症。这些特定调控基因表达的改变是通过二恶英和相关配体与AHR(一种基本的螺旋-环-螺旋蛋白,作为配体激活的转录因子)的高亲和力相互作用机制发生的。虽然在啮齿动物模型中已经很好地确定了接触与观察到的健康影响之间的关系,但在评估每天持续低水平接触这些强效环境污染物所造成的人类健康风险方面,存在相当大的科学争议。这是因为持久性或非持久性配体激活AHR与随后发展的不良健康影响有关的机制尚未确定。具体而言,我们的研究主要集中在三个方面:(1)确定TCDD在啮齿动物中的致癌性机制;(2)鉴定人与啮齿动物之间ahr依赖的转录反应网络的细胞特异性和物种差异;(3)评估TCDD和结构相关的持久性多卤芳烃致癌风险预测的相对效度因子的适用性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher J Portier其他文献

A call from 40 public health scientists for an end to the continuing humanitarian and environmental catastrophe in Gaza
  • DOI:
    10.1186/s12940-024-01097-9
  • 发表时间:
    2024-06-28
  • 期刊:
  • 影响因子:
    5.900
  • 作者:
    Leslie London;Andrew Watterson;Donna Mergler;Maria Albin;Federico Andrade-Rivas;Agostino Di Ciaula;Pietro Comba;Fernanda Giannasi;Rima R Habib;Alastair Hay;Jane Hoppin;Peter Infante;Mohamed Jeebhay;Karl Kelsey;Rokho Kim;Richard Lemen;Hester Lipscomb;Elsebeth Lynge;Corrado Magnani;Celeste Monforton;Benoit Nemery;Vera Ngowi;Dennis Nowak;Iman Nuwayhid;Christine Oliver;David Ozonoff;Domyung Paek;Varduhi Petrosyan;Christopher J Portier;Beate Ritz;Linda Rosenstock;Kathleen Ruff;Peter Sly;Morando Soffritti;Colin L. Soskolne;William Suk;Benedetto Terracini;Harri Uolevi Vainio;Paolo Vineis;Roberta White
  • 通讯作者:
    Roberta White

Christopher J Portier的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher J Portier', 18)}}的其他基金

Physiologically Based Kinetics Of Azt
Azt 的生理动力学
  • 批准号:
    6543017
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Statistical Models In Toxicology And Biochemistry
毒理学和生物化学的统计模型
  • 批准号:
    7327698
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Statistical Models In Toxicology And Biochemistry
毒理学和生物化学的统计模型
  • 批准号:
    8149012
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STATISTICAL MODELS IN TOXICOLOGY AND BIOCHEMISTRY
毒理学和生物化学的统计模型
  • 批准号:
    6289968
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STATISTICAL MODELS IN TOXICOLOGY AND BIOCHEMISTRY
毒理学和生物化学的统计模型
  • 批准号:
    6432309
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Statistical Models In Toxicology And Biochemistry
毒理学和生物化学的统计模型
  • 批准号:
    7968020
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Statistical Models In Toxicology And Biochemistry
毒理学和生物化学的统计模型
  • 批准号:
    7168889
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Statistical Models In Toxicology And Biochemistry
毒理学和生物化学的统计模型
  • 批准号:
    6681947
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
Statistical Models In Toxicology And Biochemistry
毒理学和生物化学的统计模型
  • 批准号:
    7007183
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
STATISTICAL MODELS IN TOXICOLOGY AND BIOCHEMISTRY
毒理学和生物化学的统计模型
  • 批准号:
    6106665
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

DNA repair, Cell cycle Checkpoints and Apoptosis and Bladder Cancer Risk
DNA 修复、细胞周期检查点和细胞凋亡以及膀胱癌风险
  • 批准号:
    8065522
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
DNA repair, Cell cycle Checkpoints and Apoptosis and Bladder Cancer Risk
DNA 修复、细胞周期检查点和细胞凋亡以及膀胱癌风险
  • 批准号:
    7661914
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
DNA repair, Cell cycle Checkpoints and Apoptosis and Bladder Cancer Risk
DNA 修复、细胞周期检查点和细胞凋亡以及膀胱癌风险
  • 批准号:
    8268502
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
DNA repair, Cell cycle Checkpoints and Apoptosis and Bladder Cancer Risk
DNA 修复、细胞周期检查点和细胞凋亡以及膀胱癌风险
  • 批准号:
    7848344
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Cell Cycle/Apoptosis Gene Variants and Breast Cancer Risk
细胞周期/凋亡基因变异和乳腺癌风险
  • 批准号:
    8075439
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
Cell Cycle/Apoptosis Gene Variants and Breast Cancer Risk
细胞周期/凋亡基因变异和乳腺癌风险
  • 批准号:
    7373680
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
Cell Cycle/Apoptosis Gene Variants and Breast Cancer Risk
细胞周期/凋亡基因变异和乳腺癌风险
  • 批准号:
    7658100
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
Cell Cycle/Apoptosis Gene Variants and Breast Cancer Risk
细胞周期/凋亡基因变异和乳腺癌风险
  • 批准号:
    7845617
  • 财政年份:
    2008
  • 资助金额:
    --
  • 项目类别:
NUCLEOTIDE EXCISION REPAIR/CELL CYCLE CONTROL HAPLOTYES AND LUNG CANCER RISK AND
核苷酸切除修复/细胞周期控制单倍体与肺癌风险和
  • 批准号:
    7088499
  • 财政年份:
    2006
  • 资助金额:
    --
  • 项目类别:
Cell Cycle Variants and Metastatic Prostate Cancer Risk
细胞周期变异和转移性前列腺癌风险
  • 批准号:
    7051995
  • 财政年份:
    2005
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了